News

AdvaMed’s Q4 2025 medical device litigation TV advertising report shows a strong start to the quarter followed by a typical year-end slowdown. Ad volume declined 6% from Q3, but total spending increased 6%, with November reaching a new monthly high of approximately $280K. Pelvic mesh remained the most advertised product, while hernia mesh led in overall spend, exceeding $431K. Advertising for implanted medication ports and military earplugs declined, and hip implant ads were absent for the second consecutive quarter, suggesting a potential shift in litigation focus.

Medical device mass tort TV advertising ticked up in Q3 2025, with ad volume rising 19% and each month topping 1,000 ads. August led the quarter with more than 1,200 ads and about $234,000 in spending. Pelvic mesh remained the top target, generating over 2,170 ads and $272K in spend, while hernia mesh drew the highest overall investment. Ads tied to implanted medication ports and 3M military earplugs also grew, signaling continued testing of these litigation themes.

Medical device mass tort TV advertising saw a sharp downturn in Q2 2025, with ad volume falling 61% from Q1 and spending dropping 71%, from $2.5 million to under $740,000. Activity was front-loaded in April, which accounted for the highest ad count (~1,120) and spend ($337,000), before tapering off in May (~870 ads) and June (~840 ads).

First-quarter spending on medical device injury claim ads surged to over $2.5 million for approximately 7,300 ads aired nationwide—a sharp increase from the previous quarter. Advertisers nearly tripled their spending to support over 2,200 additional ads. Much of this 160% increase occurred in January alone, when more than $1.6 million was spent to broadcast nearly 3,000 mass tort ads. Compared to previous years, estimated spending in Q1 2025 exceeded first-quarter totals by $500,000 in 2024 and nearly $1 million in 2023.

Excepting the year's previous quarter, fourth-quarter spending on medical device injury claim ads decreased, totaling over $966,000 for approximately 6,000 ads nationwide. Notably, spinal cord stimulators emerged as a new mass tort ad target, with 111 ads aired.

Excepting the year’s first quarter, third quarter spending exceeded all prior quarters since the second quarter of 2023. Estimated spending on these ads jumped by over $280,000 or 25%. 

Implanted ports remained the top medical device mass tort ad target in the third quarter as in the second and is the top medical device target of the year to date. 

• Government & Legislative Affairs 
• Legal

WASHINGTON – Today, AdvaMed, the Medtech Association, submitted a letter to the House Committee on Oversight and Accountability regarding the Committee’s consideration of an issue that threatens to undermine the foundations of our health care system: outside financing that generates mass tort litigation over important, beneficial medical devices.